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NorPM-P1
EFFECT OF RARE GENETIC VARIANTS ON ORGANIC
ANION TRANSPORTING POLYPEPTIDE 1B1
Kiander W.1, Kidron H.1, Niemi M.2
1Faculty of Pharmacy, University of Helsinki, Helsinki, Finland;
2Faculty of Medicine, University of Helsinki, Helsinki, Finland
Aims: To examine the effect of single-nucleotide polymorphisms in
the transmembrane domains of Organic Anion Transporting Polypep-
tide 1B1 (OATP1B1, SLCO1B1) on its activity.
Methods: 8 naturally occurring variants in the transmembrane
domains of OATP1B1 and a common variant (c.521T>C) which
served as a control were selected. The mutations were inserted in the
wildtype OATP1B1 gene by site-directed mutagenesis. The Bac-to-Bac
baculovirus system was used to transiently express the variant proteins
in mammalian cells (HEK293). Dichlorofluorescein and estrone-3-sul-
phate were used as substrates in cellular uptake studies to test the
activity of the variants. The effects of the polymorphisms on expres-
sion levels and localization of the variants were studied with Western
blotting and immunofluorescence microscopy.
Results: The transport activity of some of the variants in the trans-
membrane region was significantly impaired compared to wildtype
OATP1B1, while others exhibited normal or even enhanced uptake of
the study substrates. Immunofluorescence studies in cells indicate
impaired localization for some of the variants, which could at least
partly explain the decrease in activity.
Conclusion: The activity of OATP1B1 may be altered due to rare sin-
gle nucleotide polymorphisms in the transmembrane domains.
NorPM-P2
CLOPIDOGREL MARKEDLY INCREASES DASABUVIR
EXPOSURE, AND RITONAVIR INHIBITS THE
BIOACTIVATION OF CLOPIDOGREL
Itkonen M.K., Tornio A., Lapatto-Reiniluoto O., Neuvonen M.,
Neuvonen P.J., Niemi M., Backman J.
Clinical Pharmacology, University of Helsinki and Helsinki University
Hospital, Helsinki, Finland
Aims: The purpose of this clinical study was to characterize the effect
of the CYP2C8 inhibitor clopidogrel on the pharmacokinetics of the
CYP2C8 substrate dasabuvir. Because dasabuvir is routinely used in
an antiviral drug regimen containing ritonavir, a strong CYP3A4 inhi-
bitor, the secondary aims were to explore how ritonavir modifies clopi-
dogrel-dasabuvir interaction and whether ritonavir affects the
bioactivation of clopidogrel, which is partly CYP3A4-mediated.
Methods: In a four-phase cross-over study, twelve healthy volunteers
were administered clinical doses of clopidogrel, ritonavir, their combi-
nation, or placebo as pretreatments, and a single dose of dasabuvir.
The plasma concentrations of dasabuvir, clopidogrel, their metabolites,
and ritonavir were determined with liquid chromatography/mass spec-
trometry. The antiplatelet effect of clopidogrel was measured with a
turbidimetric optical detection system.
Results: Clopidogrel increased the geometric mean AUC0-1 of
dasabuvir 4.7-fold (90% CI of geometric mean ratio 3.2–6.7-fold;
p = 8 9 107), compared with placebo. When clopidogrel and riton-
avir were co-administered, dasabuvir AUC0-1 was 3.9-fold (90% CI
2.8–5.5-fold; p = 2 9 106) of that during the ritonavir phase. Riton-
avir decreased the AUC0–4 h of clopidogrel active metabolite by 51%
(90% CI 39–61%; p = 0.0001), and average platelet inhibition dimin-
ished from 51% to 31% by ritonavir (mean difference 90% CI 27%
to 12%; p = 0.0007).
Conclusion: Clinical doses of clopidogrel markedly augment dasabu-
vir exposure and inhibit the CYP2C8-mediated formation of the
dasabuvir metabolite, M1. Therefore, the risk for dasabuvir adverse
effects, i.e. QTc prolongation, may increase if clopidogrel is used con-
comitantly with dasabuvir, irrespective of ritonavir. In addition,
dasabuvir can serve as a CYP2C8 probe substrate for drug interaction
studies. Lastly, ritonavir can reduce the antithrombotic efficacy of
clopidogrel. Thus, concurrent use of clopidogrel and dasabuvir is best
avoided.
NorPM-P3
UNDERSTANDING DRUG REACTIONS USING GENOME
SEQUENCING (UDRUGS) STUDY: A NEW ZEALAND
INITIATIVE TO INVESTIGATE THE GENETICS OF ADRS
Maggo S.1, Liau Y.1, Doogue M.2, Kennedy M.1
1Pathology & Biomedical Science, University of Otago, Christchurch,
New Zealand; 2Department of Medicine, University of Otago,
Christchurch, New Zealand
Aims: UDRUGS is a New Zealand initiative to systematically collect
samples from people who have had adverse drug reactions (ADRs) to
characterize known or identify novel genetic variants associated with
rare, unusual, and severe ADRs.
Methods: Participants for the UDRUGS study are largely recruited
via referral through clinicians working in Christchurch hospital, but
also from clinicians across New Zealand. Written consent is sought
from all patients referred to the UDRUGS study. Genetic analysis lar-
gely involves Sanger sequencing of candidate genes. We have also
used whole exome sequencing (WES) or whole genome sequencing
(WGS) for a subset of cases. We communicate relevant research find-
ings back to the participants and/or the referring clinician citing guide-
lines from the Clinical Pharmacogenetics Implementation Consortium
(CPIC).
Results: To date we have collected ~100 samples across 12 general
drug classes. The majority of cases recruited have been for ADRs to
antidepressants, drugs affecting immune response (azathioprine) and
cardiovascular medication (statins and medication used for hyperten-
sion). For antidepressants, we have genotyped 37 patients, and
observed that 65% of the cohort had at least one non-functional
CYP2D6 allele (p < 0.01, compared with CYP2D6 EXAC NFE). In
addition we have carried out WES on participants with recurrent sta-
tin-myalgia, and participants with ACEi induced angioedema. For both
cohorts our analyses have identified rare variants which require further
validation.
Conclusion: We have developed a programme for studying severe,
rare or unusual ADR cases resulting from pharmacological treatment.
Genomic analyses should eventually identify most genetic variants that
predispose to ADRs, enabling a priori detection of such variants with
high throughput DNA tests. Establishing UDRUGS, a New Zealand
DNA bank that can receive ADR samples and associated clinical data,
will ensure we contribute to and benefit from such research.
© 2018 The Authors
Basic & Clinical Pharmacology & Toxicology © 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Basic & Clinical Pharmacology & Toxicology, 123 (Suppl. 1), 3–14
3
NorPM-P4
DIFFERENCES IN SENSITIVITY TO DETECT TIME-
DEPENDENT INACTIVATION OF CYP2C8 BETWEEN
RECOMBINANT EXPRESSED ENZYMES AND HUMAN
LIVER MICROSOMES
Kahma H.1, Filppula A.M.1, Launiainen T.1, Viinam€aki J.1,
Evangelista E.A.2, Totah R.A.2, Backman J.T.1
1Clinical Pharmacology, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland; 2Medicinal Chemistry,
University of Washington, Seattle, United States
Aims: Clopidogrel acyl-b-D-glucuronide causes strong time-dependent
inactivation of CYP2C8 in human liver microsomes (HLMs). How-
ever, in preliminary studies on the inactivation mechanism, we were
unable to detect inactivation of CYP2C8 by clopidogrel glucuronide in
Supersomes. Therefore, we investigated the performance of different
CYP2C8 sources in detection of time-dependent inactivation.
Methods: Time-dependent inactivation of CYP2C8 by clopidogrel
acyl-b-D-glucuronide (100 µM), gemfibrozil 1-O-b-glucuronide
(100 µM) and amiodarone (100 µM) was studied in HLMs and three
recombinant human CYP2C8 preparations (Supersomes, Bactosomes
and EasyCYP Bactosomes) using amodiaquine N-demethylation as the
marker reaction. The inactivation kinetics of CYP2C8 by clopidogrel
acyl-b-D-glucuronide (5–250 µM) was studied in Supersomes and
Bactosomes.
Results: Time-dependent inactivation of CYP2C8 by amiodarone and
gemfibrozil glucuronide was observed in all enzyme preparations, with
moderate variability between preparations. However, the extent of
inactivation by clopidogrel glucuronide varied markedly between dif-
ferent preparations, as well as between different Supersome lots. While
clopidogrel glucuronide (100 µM) caused strong inactivation of
CYP2C8 in HLMs (72% and 16% inhibition with and without 30-min
preincubation, respectively) and in one Supersome lot (54% and 0%
inhibition with and without preincubation, respectively), significant
inactivation could not be reliably detected in two other lots. In Bacto-
somes, the KI and kinact of clopidogrel glucuronide (14 µM and
0.054 min1) were close to those determined previously in HLMs
(9.9 µM and 0.047 min1).
Conclusion: The results show that there are differences between
enzyme sources and between lots of recombinant enzymes in sensitiv-
ity to detect inactivation of CYP2C8. The risk of false negatives
should be taken into account when recombinant CYP enzymes are
used to identify time-dependent inactivators of CYP enzymes.
NorPM-P5
NEW CONCEPTS IN DISEASE CLASSIFICATION, TOWARD
GENE BASED DIAGNOSIS, SUBTYPES AND PREDICTION OF
DRUG RESISTANCE IN MALIGNANT B-CELL DISEASES
Johnsen H.E., Sønderkær M., Brøndum R.F., Schmitz A., Bødker J.S.,
El-Galaly T.C., Bøgsted M., Dybkær K.
Research Section, Department of Haematology, Clinical Cancer
Research Center and Department of Clinical Medicine, Aalborg
University Hospital and Aalborg University, Aalborg, Denmark
Aims: We perceive the future of cancer treatment as being in the
development of “personalised medicine” strategies and malignant B-
cell diseases (MBCD) is an excellent example, where this approach
can be clinically validated.
Our concept is to take individual gene expression variability and new
classifications into account by new strategies of disease diagnosis, new
subtyping and new drug specific prediction. Here we present a sum-
mary of our work with the primary aims to give useful information to
clinical decision making.
Methods: Tumor biopsies from 4,226 patients with Affymetrix U133
plus 2.0 microarray mRNA expression datasets, in collaborations and/
or on line from 21 newly diagnosed/untreated cohorts with lymphoid
leukemia, non-Hodgkin lymphoma or multiple myeloma. Powerful
methods for phenotyping by multi omics, diverse preclinical cell line
models and bioinformatic tools for large data set analysis allowed us
to address new classifications exemplified by diagnostic analysis gene
signature (DAGS), B-cell associated gene signature (BAGS) and resis-
tant gene signature (REGS) assignment of individual tumors.
Results: The resultant tumor assignments in the available clinical
datasets exhibited the following:
1. Individual DAGS have a significant diagnostic accuracy; (Table 1).
2. Individual BAGS disease subtypes have prognostic impact, and
therefore reflect pathogenesis; (Figure 1).
3. Individual REGS for specific drug resistance has predictive infor-
mation documented by its prognostic impact; (Figure 2).
Consequently, we have prepared an R-package based tool: http://www.
hemaclass.org/ relevant for implementation of PM in the clinical set-
ting.
Conclusion: The results “proves our concept” that individual variabil-
ity and new classification by gene expression may allow more precise
diagnostics, subtyping and identify drug specific resistance that will
reduce overtreatment, increase the “Value in Health Care” and validate
the PM strategy and goals.
NorPM-P6
HEMATOLOGICAL CANCER PATIENTS’ POSITION ON
PRECISION MEDICINE – A QUESTIONNAIRE SURVEY
Sommer M.1, Nielsen M.M.1, Vesteghem C.2, Bøgsted M.2, Dybkjær K.2,
Johnsen H.E.1, El-Galaly T.C.1, Brøndum R.F.1
1Department of Hematology, Aalborg University Hospital, Aalborg,
Denmark; 2Department of Clinical Medicine, Aalborg University,
Aalborg, Denmark
Aims: Precision Medicine has gained increased medical and political
attention in recent years. In Denmark, this has resulted in The National
Strategy for Precision Medicine 2017–2020 and development of a
national genome center. In 2016, the Danish Ministry of Health and
Danish Regions performed a population-based survey of the public’s
position on precision medicine. However, to our knowledge no study
has investigated patients’ position on this area. Therefore, the aim of
this study was to investigate hematological cancer patients’ position on
precision medicine compared to the healthy population.
Methods: Data was collected using a questionnaire developed by
ADVICE Communication Agency for the population-based survey and
on behalf of the Danish Ministry of Health and Danish Regions. Eligi-
ble participants were hematological cancer patients affiliated to the
Department of Hematology, Aalborg University Hospital. The ques-
tionnaire was administered electronically through REDCap or on
paper. Data was collected anonymously.
Results: Between October 2017 and January 2018, we enrolled 286
patients (median age; men 66 years, women 67 years). The study pop-
ulation had a higher median age compared to the public (n = 1005)
(median age; men 60.5 years, women 53 years) and a lower education
level. We found that 84% of the patients had none or limited knowl-
edge about gene testing compared to 55% of the public (p = 0.0001).
97% of the patients found gene testing and precision medicine interest-
ing compared to 52% of the public (p = 0.0001). Furthermore, 92% of
the patients were positive towards genetic research compared to 40%
of the public (p = 0.0001).
Conclusion: We have identified a difference in the knowledge level
between hematological cancer patients and the public. A difference,
which should be addressed in order to optimize and support patient
dialogue in a precision medicine context.
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NorPM-P7
MEDICATIONS DURING PREGNANCY: EFFECTS ON
NEURODEVELOPMENTAL DISORDERS IN CHILDHOOD
AND EPIGENETIC OUTCOMES
Nordeng H.1, Gervin K.2, Eskeland R.3, Paulsen R.4, Samuelsen S.O.5,
Sandve G.K.6, Lyle R.7
1Pharmacoepidemiology and Drug Safety, School of Pharmacy,
University of Oslo, Oslo, Norway; 2Pharmacoepidemiology and Drug
Safety, School of Pharmacy, University of Oslo, Oslo, Norway;
3Department of Biosciences, University of Oslo, Oslo, Norway;
4Department of Pharmaceutical Biosciences, School of Pharmacy,
University of Oslo, Oslo, Norway; 5Department of Mathematics,
University of Oslo, Oslo, Norway; 6Department of Informatics,
University of Oslo, Oslo, Norway; 7Department of Medical Genetics,
Oslo University Hospital and School of Pharmacy, University of Oslo,
Oslo, Norway
Aims: To present the PharmaTox initiative and our on-going studies
to assess effects of pharmaceuticals on human neurodevelopment and
neurotoxicity
Rational: The fetal period is believed to be one of the most sensitive
periods for brain development. During this period, neurons are created,
differentiate and migrate to form the various parts of the brain. The
theoretical potential of neurotoxicity of pharmaceuticals is related to
their ability to pass the blood-brain barrier and impact on the develop-
ing fetal nervous system. The PharmaTox Strategic Research Initiative
was established in 2015 uniting strong research groups in pharma-
coepigemiology, toxicology, epigenetics, bioinformatics and statistics
at the University of Oslo, Norway.
Methods: A primary data source is epidemiological data from the
Norwegian Mother and Child (MoBa) cohort, along with correspond-
ing genetic and epigenetic data derived from blood samples of infants
in MoBa. Moreover, to give biological plausible molecular and cellular
mechanisms of neurotoxicity, a CNS pharmacology safety model
(chicken embryo) and human embryonic stem cells are used. Advanced
statistical methods, medical bioinformatics and microarray technology
are an integrated part of this research.
Results: Several results have been published in relation to paracetamol
use in pregnancy. An association between long-term use of paraceta-
mol with increased risk of ADHD was recently published, as well as
findings of altered DNA-methylation patterns among children with
ADHD diagnosis prenatally exposed to long-term use of paracetamol.
Preliminary results from the chicken embryo model suggests that
paracetamol and other medications change the expression of specific
microRNAs.
Conclusion: Novel insight into neurotoxicity of pharmaceuticals can
be obtained by using a translational approach, advanced statistical
methods, medical bioinformatics and microarray technology on epi-
demiological and human genetic data in combination with experimen-
tal in vivo and intro models.
NorPM-P8
AN OPTIMIZED PREDICTION FRAMEWORK TO ASSESS
THE FUNCTIONAL IMPACT OF PHARMACOGENETIC
VARIANTS
Zhou Y.1, Mkrtchian S.1, Kumondai M.2, Hiratsuka M.2, Lauschke V.1
1Department of Physiology and Pharmacology, Karolinska Institutet,
Stockholm, Sweden; 2Laboratory of Pharmacotherapy of Life-Style
Related Diseases, Tohoku University, Sendai, Japan
Aims: Prediction of phenotypic consequences of mutations constitutes
an important aspect of precision medicine. Current computational tools
mostly rely on evolutionary conservation and have been calibrated on
variants associated with disease, which poses problems for assessment
of variants in poorly conserved pharmacogenes. Therefore, we aimed
to develop a functional prediction framework optimized for
pharmacogenetics assessments that significantly outperformed current
predictive algorisms.
Methods: Experimental functionality data of 244 pharmacogenetic
missense variants distributed across 21 ADME genes were obtained to
optimize 18 current functionality prediction models. Specifically, 123
training variants were randomly assigned for the optimization and the
best combination of optimized models were validated by the rest 121
variants.
Results: Compared to current models with low predictive power, our
prediction model achieved 92% sensitivity and 95% specificity for
loss-of-function and functionally neutral variants. This result was also
confirmed in an independent validation cohort.
Conclusion: This ADME-optimized prediction framework signifi-
cantly improves in silico functionality assessment of pharmacogenetic
variants, thereby facilitating the translation of uncharacterized variants
into pharmacogenetic recommendations and providing a further step
towards the leveraging of Next-Generation Sequencing data for the
personalization of pharmacological treatment.
NorPM-P9
EFFECTS OF GENETIC VARIANTS OF HUMAN NICOTINIC
RECEPTOR SUBUNITS CHRNA3, CHRNA4, CHRNA5 ON
NICOTINE DEPENDENCE AND SMOKING CESSATION
Muderrisoglu A.1, Babaoglu E.2, Korkmaz E.T.2, Kalkisim S.1,
Karabulut E.3, Emri S.4, Babaoglu M.O.1
1Department of Pharmacology, Hacettepe University Faculty of
Medicine, Ankara, Turkey; 2Department of Chest Diseases, Hacettepe
University Faculty of Medicine, Ankara, Turkey; 3Department of
Biostatistics, Hacettepe University Faculty of Medicine, Ankara,
Turkey; 4Department of Chest Diseases, Altynba� University Faculty
of Medicine, Istanbul, Turkey
Aims: To investigate the effects of genetic variants in nicotinic recep-
tor subunits of CHRNA3 rs578776, CHRNA4 rs1044396-rs1044397,
and CHRNA5 rs16969968 on the heaviness of nicotine dependence
and outcomes of smoking cessation treatments at the 12th week in a
Turkish population.
Methods: We recruited 130 smokers and 130 non-smokers for this
study. The heaviness of nicotine dependence was determined by Fager-
str€om Test for Nicotine Dependence and CO levels. Scores e7 were
considered as high nicotine dependence (n = 60), scores <7 were con-
sidered as medium or low nicotine dependence (n = 70). Treatment
groups were nicotine replacement therapy (NRT, n = 40), bupropion
(n = 47), bupropion+NRT (n = 15) and varenicline (n = 28). PCR-
RFLP was used for genotyping.
Results: We found an association between the heaviness of nicotine
dependence and AA genotype for the CHRNA4 rs1044396 variant
(p = 0.02) and, with A allele for the CHRNA5 rs16969968 variant
(p = 0.003). Frequencies for the CHRNA4 rs1044396 GG, GA, and
AA genotypes were 30%, 53.3%, 16.7% in high nicotine-dependent
smokers; 22.9%, 52.9%, 24.3% in medium or low nicotine-dependent
smokers; 30%, 34.6%, 35.4% in non-smokers, respectively. Frequen-
cies for the CHRNA5 rs16969968 G and A alleles were 58.3%, 41.7%
in high nicotine-dependent smokers; 42.1%, 57.9% in medium or low
nicotine-dependent smokers; 40%, 60% in non-smokers, respectively.
We also found an association between T allele for the CHRNA3
rs578776 genetic variant and failure of bupropion+NRT treatment
(p = 0.033). C and T allele frequencies in the bupropion+NRT group
were: 83.3% and, 16.7% in quitters; 44.4% and, 55.6% in non-quitters,
respectively.
Conclusion: AA genotype for the CHRNA4 rs1044396 variant and A
allele for the CHRNA5 rs16969968 variant was associated with a lower
level of nicotine dependence. The T allele for the CHRNA3 rs578776
genetic variant was associated with failure of smoking cessation ther-
apy in patients treated with bupropion+NRT. Supported by Hacettepe
University grant TSA-2017-12810.
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NorPM-P10
EFFECTS OF A GENETIC POLYMORPHISM OF HUMAN
CYP2B6 ON NICOTINE DEPENDENCE AND SMOKING
CESSATION THERAPY
Muderrisoglu A.1, Babaoglu E.2, Korkmaz E.T.2, Ongun M.C.1,
Karabulut E.3, Emri S.4, Babaoglu M.O.1
1Department of Pharmacology, Hacettepe University Faculty of
Medicine, Ankara, Turkey; 2Department of Chest Diseases, Hacettepe
University Faculty of Medicine, Ankara, Turkey; 3Department of
Biostatistics, Hacettepe University Faculty of Medicine, Ankara,
Turkey; 4Department of Chest Diseases, Altınbas University Faculty
of Medicine, Istanbul, Turkey
Aims: CYP2B6 is responsible for the metabolism of nicotine and bupro-
pion. The aim of this study was to investigate the effects of CYP2B6
rs2279343 genetic polymorphism on the heaviness of nicotine dependence
and smoking cessation after 12 weeks of treatment in a Turkish population.
Methods: A total of 260 volunteers; 130 smokers and 130 non-smo-
kers were recruited. Determination of the heaviness of nicotine depen-
dence in the smokers was performed by Fagerstr€om Test for Nicotine
Dependence and verified by breath CO measurements. Scores e7 were
considered as high nicotine dependence (n = 60), scores <7 were con-
sidered as medium or low nicotine dependence (n = 70). There were
four treatment groups: nicotine replacement therapy (NRT, n = 40),
bupropion (n = 47), bupropion+NRT (n = 15) and varenicline
(n = 28). PCR-RFLP was used for genotyping.
Results: Frequencies for the AA, AG and GG genotypes were similar
in all groups: 43.3%, 48.3%, 8.3% in high nicotine-dependent smokers;
45.7%, 44.3%, %10 in medium or low nicotine-dependent smokers;
46.2%, 40.8%, 13.1% in non-smokers, respectively (p ≥ 0.05). Also,
we found no association between CYP2B6 rs2279343 polymorphism
and cessation rates of smokers after 12 weeks of treatment (p ≥ 0.05).
Conclusion: This study showed no association of CYP2B6 rs2279343
polymorphism with the heaviness of nicotine dependence and with
smoking cessation after 12 weeks of treatment.
Supported by Hacettepe University grant, TSA-2017-12810.
NorPM-P11
PROTEOMIC ANALYSIS OF SERUM FOR EARLY
BIOMARKERS OF HEPATOLENTICULAR DEGENERATION
IN MALE ADOLESCENTS
Bazylak G.1, Pan T.-L.2, Wang P.-W.2, Chang W.-N.3, Hung Y.-C.4
1Department of Pharmaco-Bromatology & Molecular Nutrition,
Nicolaus Copernicus University, Collegium Medicum, Faculty of
Pharmacy, Bydgoszcz, Poland; 2School of Traditional Chinese
Medicine, College of Medicine, Chang-Gung University, Taoyuan,
Taiwan; 3Department of Neurology, Chang-Gung Memorial Hospital,
Kaohsiung, Taiwan; 4Department of Chinese Internal Medicine,
Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
Aims: The rare autosomal recessive defects in the copper transporting
ATPase gene (ATP7B), known as Wilson’s disease (WD), leading to
increased accumulation of copper in liver, cornea and basal ganglia
and cause liver cirrhosis combined with variable neuropsychological
manifestations, but early and personalized diagnosis to differentiate
between asymptomatic and progressive stage of WD (hepatolenticular
degeneration) in humans are still challenging issue.
Methods: Proteome profiles of venus blood serum from WD male ado-
lescent subjects (mean age 13.2  1.2 years) were separated by 2-D gel
electrophoresis and identified by peptide mass fingerprinting (MALDI-
MS). Western blotting and immunohistochemistry were used to validate
the protein expression in situ. Dot-blot was used to prove the high-level
expression of fibrinogen in both homozygous and heterozygous WD sub-
jects and compared to age matched healthy controls (HC) and patients
with confirmed blood stasis cardiovascular symptoms (BSC). The partial
N-terminal amino acid residues sequencing and protein database searching
was used to verify the 2-DE results.
Results: Total 31 protein spots with difference between WD and HC
subjects were counted and identified. Specifically, 22 protein spots
covering fibrinogen-c family, fibrinogen-a group, fibrinogen-b chain,
Apo-family protein (A1, E, J), acute phase proteins (a2-macroglobulin,
haptoglobin-a), antithrombin III, complement C3 fragment, serotrans-
ferrin, transthyretin and orosomucoid-2 were found in the significantly
more abundant quantity in the WD subjects.
Conclusion: The initial liver cirrhosis accompanied with acute oxida-
tive stress caused by continuos development of WD may account for
the abnormal increase of fibrinogen level (significantly more than
observed in BSC) which could lead to the subtle but clinically relevant
disturbances in the function of coagulation system of WD patients,
thus our data support some results reported by Schaefer et al. (2015).
NorPM-P12
INCREASED SUM CONCENTRATION OF VENLAFAXINE
AND O-DESMETHYLVENLAFAXINE AND RISK OF SIDE
EFFECTS IN COMBINED CYP2D6/CYP2C19 POOR
METABOLIZERS
Kringen M.K., Haslemo T., Molden E.
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo,
Norway
Aims: The aim of this study was to evaluate the combined impact of
CYP2D6 and CYP2C19 genotypes on the active sum of venlafaxine
and O-desmethylvenlafaxine serum concentrations.
Methods: Serum concentrations of venlafaxine and O-desmethylvenla-
faxine measured in patients with available CYP2D6 and CYP2C19 and
genotypes were included from a Therapeutic Drug Monitoring (TDM)
service at Diakonhjemmet Hospital in Oslo (Norway). Patients were
divided into different subgroups according to genotypes: Extensive
metabolizers (EM), intermediate metabolizers (IM) and poor metaboliz-
ers (PM) of CYP2D6 and CYP2C19, respectively. The impact of
CYP2D6 and CYP2C19 genotypes on dose-adjusted sum concentration
of venlafaxine and O-desmethylvenlafaxine, the pharmacological active
moiety, was evaluated using multiple linear regression analysis.
Results: Overall, 980 patients were included in this study. The dose-
adjusted sum concentration of venlafaxine and O-desmethylvenlafaxine
was significantly associated with CYP2D6 and CYP2C19 genotypes
(p < 0.001). The number of combined carriers of either CYP2D6 and
CYP2C19 IMs or PMs was in total 62 (6.3% of the total population). For
combined CYP2D6/CYP2C19 IMs (n = 58; 5.9% of total) and PMs
(n = 4; 0.4% of total), the sum concentration increased by 40% and
380%, respectively, compared to combined EMs (n = 256) (p < 0.001).
Conclusion: Combined CYP2D6 and CYP2C19 PMs had a 5-fold
higher sum concentration of venlafaxine and O-desmethylvenlafaxine
compared to combined EMs. The subpopulation of combined PMs,
representing 1 per 200 Caucasian patients, is therefore at substantial
risk of side effects during venlafaxine treatment.
NorPM-P13
DOSE DEPENDENT CYP2D6 INHIBITION BY BUPROPION
AND LEVOMEPROMAZINE
Haslemo T.1, Arnestad M.2, Molden E.1
1Centre for Psychopharmacology, Diakonhjemmet Hospital, Oslo,
Norway; 2Department of Forensic Sciences, Section of Forensic
Toxicology, Oslo University Hospital, Oslo, Norway
Aims: The aim of this study was to compare the dose-dependent
CYP2D6-inhibitory effect of bupropion (BUP) and levomepromazine
(LEV) using O/N-desmethylvenlafaxine as biomarker.
Methods: Serum concentrations of O-desmethylvenlafaxine and N-
desmethylvenlafaxine measured in patients co-treated with different
CYP2D6-inhibitors were retrieved from a therapeutic drug monitoring
database at Diakonhjemmet Hospital (Oslo, Norway). Metabolic ratio
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(MR) O-desmethylvenlafaxine/N-desmethylvenlafaxine in two dose
groups of BUP (≤150 mg and >150 mg) and LEV (≤50 mg and
>50 mg) were compared with a reference group of patients receiving
the potent CYP2D6 inhibitors fluoxetine (FLU) or paroxetine (PAR).
Groups were compared using a multiple linear regression model.
Results: A total of 158 patients were included in this study. All patients
were treated with venlafaxine in combination with one of the following
CYP2D6 inhibitors: BUP ≤150 mg/day (n = 54), BUP>150 mg/day
(n = 35), LEV ≤50 mg/day (n = 20), LEV>50 mg/day (n = 32) or
FLU/PAR (n = 17). MR in patients receiving high doses of BUP or LEV
were not significantly different from the reference group (p > 0.15),
while patients receiving low doses BUP or LEV had higher MR than the
reference groups (+417% p < 0.001 and +297% p < 0.001 respectively).
Conclusion: Doses in the higher therapeutic range of bupropion and
levomepromazine show a similar CYP2D6 inhibition as the potent
inhibitors fluoxetine and paroxetine. The dose-dependent CYP2D6-
inhibitory effect of bupropion and levomepromazine is important to
consider regarding interaction risk in clinical practice.
NorPM-P14
ENANTIOSPECIFIC PHARMACOGENOMICS OF
FLUVASTATIN
Hirvensalo P.1, Tornio A.1, Neuvonen M.1, Kiander W.2, Kidron H.2,
Paile-Hyv€arinen M.1, Tapaninen T.1, Backman J.1, Niemi M.1
1Department of Clinical Pharmacology, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland; 2Division of
Pharmaceutical Biosciences, University of Helsinki, Helsinki, Finland
Aims: Large interindividual variability exists in the pharmacokinetics
and effects of fluvastatin. Our aim was to investigate how sequence
variations in pharmacokinetic genes affect fluvastatin exposure.
Methods: A single 40 mg oral dose of racemic fluvastatin was admin-
istered to 200 healthy volunteers. Plasma 3R,5S- and 3S,5R-fluvastatin
enantiomer concentrations were measured using liquid chromatogra-
phy-tandem mass spectrometry and 379 genes related to pharmacoki-
netics were fully sequenced using massive parallel sequencing.
Results: The CYP2C9 decreased-function allele CYP2C9*3 (rs1057910;
c.1075A>C; p.Ile359Leu) was associated with increased area under the
plasma concentration-time curve (AUC) of both fluvastatin enantiomers.
The AUC of 3R,5S-fluvastatin was 67% (p = 3.44 9 109) and that of
3S,5R-fluvastatin was 94% (p = 2.80 9 1012) larger per copy of the
variant allele. In addition, the SLCO1B1 decreased-function rs4149056
(c.521T>C; p.Val174Ala) variant increased the AUC of 3R,5S-fluvasta-
tin by 34% per minor allele (p = 7.55 9 108), but had no effect on
3S,5R-fluvastatin. In vitro, however, the two enantiomers were similarly
transported by OATP1B1 (encoded by SLCO1B1).
Conclusion: These results indicate that CYP2C9*3 plays an important
role in determining interindividual variability in fluvastatin pharmacoki-
netics. Furthermore, SLCO1B1 genotype affects the pharmacokinetics of
the pharmacologically more active 3R,5S-enantiomer of fluvastatin. This
knowledge may aid in individualizing cholesterol-lowering therapy.
NorPM-P16
MECHANISM OF IMATINIB-RESISTANCE – MICRORNA-212/
ABCG2-AXIS CONTRIBUTES TO DEVELOPMENT OF
IMATINIB-RESISTANCE IN LEUKEMIC CELLS
K€ahler M.1, Ruemenapp J.1, Gonnermann D.2, Nagel I.1, Bruhn O.1,
Haenisch S.1, Ammerpohl O.3, Wesch D.2, Cascorbi I.1, Bruckmüller H.1
1Institute of Experimental and Clinical Pharmacology, University
hospital Schleswig-Holstein, Kiel University, Kiel, Germany; 2Institute
of Immunology, University hospital Schleswig-Holstein, Kiel
University, Kiel, Germany; 3Institute of Human Genetics, University
hospital Schleswig-Holstein, Kiel University, Kiel, Germany
Aims: The hematopoietic malignancy chronic myeloid leukemia
(CML) is caused by translocation between chromosomes 9 and 22
leading to formation of the Philadelphia chromosome and the BCR-
ABL fusion gene. Although the tyrosine-kinase inhibitor (TKI)
imatinib led to tremendous treatment success, the development of
resistances against imatinib is an emerging problem. Beside BCR-
ABL-dependent mechanisms (e.g. BCR-ABL amplification/overexpres-
sion, point mutations), BCR-ABL-independent mechanisms occur,
which can be linked in part to dysregulation of ATP-binding cassette
(ABC)-transporters leading to increased TKI efflux, potentially caused
by changes in microRNA expression or DNA-methylation. In an
in vitro-imatinib-resistance model using K-562 cells, microRNA-212
was identified to be deregulated and inversely correlated to ABC-trans-
porter ABCG2 expression, targeting its 3’-UTR.
Methods: To analyze the functional impact on drug sensitivity,
transfection experiments with microRNA-mimics and –inhibitors
were performed to investigate their effect on imatinib-susceptibility
in sensitive and resistant leukemic cell lines. In addition the
methylation status of miR-212 and ABCG2 promoter regions were
analyzed.
Results: Under imatinib treatment, miR-212 inhibition led to
enhanced cell viability (p = 0.01), reduced apoptosis (p = 0.01)
and cytotoxicity (p = 0.03). These effects were only observed in
treatment-na€ıve cells but not in cells resistant to various imatinib-
concentrations (0.1 lM to 2 lM). In treatment-na€ıve cells inhibition
of miR-212 resulted in ABCG2 upregulation and increased
ABCG2-dependent efflux. In addition, in 0.5 and 2 lM IM-resistant
sublines we observed a hypermethylation of the miR-212 pro-
moter region, whereas the ABCG2 gene methylation status was not
altered.
Conclusion: In summary, the miR-212/ABCG2-axis influences ima-
tinib-susceptibility and contributes to development of imatinib-resis-
tance. Our data reveal new insights into mechanisms initiating
imatinib-resistance in leukemic cells.
NorPM-P18
IMMUNOGENETICS AND PROGNOSIS OF PROSTATE
CANCER: FIRST RESULTS
Dreussi E.1, Zanusso C.1, Romualdi C.2, Gagno S.1, Mattia E.D.1,
Romanato L.1, Sartor F.1, Bortolus R.3, Quartuccio L.4, Cecchin E.1,
Toffoli G.1
1Experimental and Clinical Pharmacology, National Cancer Institute,
Aviano (Pordenone), Italy; 2Department of Biology, University of
Padova, Padova, Italy; 3Department of Radiation Oncology, National
Cancer Institute, Aviano (Pordenone), Italy; 4Rheumatology Clinic,
Department of Medical and Biological Sciences, University Hospital
‘Santa Maria della Misericordia’, Udine, Italy
Aims: Many efforts are still necessary to determine robust pharmaco-
genetics (PGx) biomarkers to be implemented in the clinical practice
to advance the field of personalized medicine in cancer treatment. In
this regard, one clinical model of interest is prostate cancer (PCa). The
primary aim of this study is the identification of new biomarkers of
biochemical recurrence (BCR) analyzing polymorphisms (SNPs) of
genes involved in immune system. The secondary aim is the determi-
nation of biomarkers of overall survival (OS). These new biomarkers,
if validated, could be implemented in the electronic clinical record to
personalize patients’ treatment.
Methods: 418 Caucasian patients affected by clinically localized PCa
treated with RT as primary therapy were enrolled. The genetic analyses
of 447 SNPs in genes of immune system were determined in germline
DNA samples using a VeraCode (Illumina) platform. Multivariate
COX regression was applied to identify the prognostic role of SNPs in
terms of both BCR and OS. Significant associations were determined
according to p-value (<0.05) and q-value (<0.15), defined according to
the False discovery rate (FDR) method.
Results: 19 SNPs were significantly associated with BCR. Interest-
ingly, these SNPs addressed in an independent way the key role of
PDL1, VEGFR, FOXO3, SMAD3, SMAD2, and IL4R, that are involved
in angiogenesis and TGFb pathway.
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The rs3918262-MMP9, rs7692791-VEGFR, and rs2034967-VEGFR
can predict OS, reinforcing the importance of angiogenesis in this clin-
ical setting.
Conclusion: This study identified the key role of SNPs impacting
immune system activity in the prediction of BCR and OS, highlighting
the relevance of angiogenesis in this setting. The prognostic role of
these SNPs is going to be tested in a replication set of 131 PCa
patients. These analyses are needed to hopefully offer new biomarkers
to optimize PCa patients’ management through the development of
innovative and user-friendly IT tools.
NorPM-P19
DEVELOPMENT OF AN INTEGRATED HEALTH IT
PLATFORM FOR A PRECISE AND COST-EFFECTIVE
THERAPY IN ONCOLOGY
Roncato R.1, Cin L.D.2, Mezzalira S.3, Comello F.1, Bignucolo A.1,
Giollo L.4, D’Errico S.4, Emili L.5, Carbone V.5, Guardascione M.2,
Mattia E.D.2, Toffoli G.2, Cecchin E.2
1Experimental and Clinical Pharmacology, Aviano (PN), Italy;
2National Cancer Institute – CRO Aviano, Aviano (PN), Italy;
3Department of Pharmaceutical and Pharmacological Science,
University of Padova, Padova, Italy; 4Insiel Mercato, Trieste, Italy;
5Promeditec, Trieste, Italy
Aims: The integration of the pharmacogenetic data in the electronic
clinical record and the development of a decision support system
could be helpful for prescribing the most efficacious and cost-effec-
tive pharmacological therapy available. This is particularly relevant in
oncology, where the therapeutic index of drugs is limited and the
cost of therapies is high. The aim of the project is to radically inno-
vate the prescriptive process of oncological medications by providing
the prescriber an IT infrastructure for the automated management
of the patient’s molecular data that will be translated into specific
indications.
Methods: The most up-dated literature data will be mined to extract a
list of gene-drug interactions based on the most recent published
guidelines to provide a list of the most relevant genetic information to
be included in the patients clinical health record together with the cor-
responding pharmacogenetic guidelines.
Results: Public available guidelines were reviewed and compared to
reach a consensus in terms of gene-drug pairs considered, their differ-
ent level and classification of evidence rated basing on a scoring sys-
tem, the therapeutic strategy recommended and the clinical impact of
pre-emptive PGx test. Information on the strength of the recommenda-
tion (classification of recommendation, level of evidence and clinical
impact) were considered necessary to be integrated in the prescribing
system along with the therapeutic recommendation. A prototype of a
decision support system is being developed through the partnership
with two high tech companies active in Italy the healthcare system
computerization.
Conclusion: Coordinated efforts through partnership are able to put
together scientific and clinical expertise in the oncologic pharmacoge-
nomic field, to implement the pre-emptive pharmacogenomic approach
in the clinical practice in Italy, and to demonstrate its benefit in both
patients clinical outcome and quality of life, with an economic advan-
tage for the healthcare system.
NorPM-P20
MAJOR INFLUENCE OF THE CYP2D6*41 ALLELE ON
CYP2D6 METABOLIZER PHENOTYPE – A STUDY ON 1,021
VENLAFAXINE-TREATED PATIENTS
Haslemo T.1, Eliasson E.2, Jukic M.3, Ingelman-Sundberg M.3,
Molden E.1
1Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo,
Norway; 2Department of Laboratory Medicine, Karolinska Institutet,
Stockholm, Sweden; 3Department of Physiology and Pharmacology,
Karolinska Institutet, Stockholm, Sweden
Aims: To compare the in vivo CYP2D6 metabolism encoded by the
*9, *10 and *41 alleles, and assess the phenotype overlap between car-
riers of these variants with non-coding (null) alleles and null/null carri-
ers (poor metabolizers, PMs).
Methods: The study included 1,021 patients from a therapeutic drug
monitoring service performing both drug concentration analyses and
genotyping. Absence of comedication with CYP2D6 inhibitors or
antiepileptic enzyme inducers was confirmed for all patients. Metabolic
ratio (MR) of O/N-desmethylvenlafaxine, a recently validated CYP2D6
biomarker, was matched with each patient’s CYP2D6 genotype. In
addition to *9, *10 and *41, the genotype assay comprised *3,*4,*5
and*6 null alleles, as well as gene duplication. MRs in carriers of *9,
*10 or *41 combined with wild type (*1) or null alleles were com-
pared by Mann-Whitney tests. In addition, the degree of subgroup
overlaps in MR was calculated from direct observations, and a multi-
ple linear regression analysis performed to provide MR subgroup esti-
mates adjusting for covariates.
Results: The MR of O/N-desmethylvenlafaxine was lower in *41 than
*9 or *10 carriers both combined with *1 and null alleles (p < 0.002).
In *41/null carriers (n = 30), MRs of 26 patients (86.7%) were in the
range of null/null carriers (n = 95) compared to three out of 17 carriers
of *9/null or *10/null (17.4%). The multiple linear regression analysis
provided MR estimates of 0.47, 1.33, 3.55, and 9.54, respectively, in
carriers of null/null,*41/null, *9-*10/null, and*1/null (n = 269). In the
multiple linear regression analysis, CYP2D6 genotype explained
60.7% of the overall variability in MR.
Conclusion: CYP2D6*41 encodes significantly lower CYP2D6 meta-
bolism in vivo than *9 and *10. The majority of *41/null carriers
express a CYP2D6 phenotype within the range of null/null carriers.
Thus, pharmacogenetic assays for clinical routine and research should
include CYP2D6*41 to capture most functional PMs.
NorPM-P21
PRELIMINARY RESULTS OF THE CLINICAL TRIAL
GENOTYPE-PHENOTYPE CORRELATION OF DRUG-
METABOLIZING ENZYMES
Böhm R.1, Bruckm€uller H.1, H€ubenthal M.2, Siegmund W.3, Oswald
S.3, H€ocker J.4, Franke A.2, Cascorbi I.1
1Institut f€ur Experimentelle und Klinische Pharmakologie, Campus
Kiel, Kiel, Germany; 2IKMB, UKSH, Campus Kiel, Kiel, Germany;
3Institut f€ur Pharmakologie, Ernst Moritz Arndt Universit€at,
Greifswald, Germany; 4Klinik f€ur An€asthesiologie und operative
Intensivmedizin, Friedrich-Ebert-Krankenhaus, Neum€unster, Germany
Aims: To detect new genetic variants with impact on drug metabolism
and to test the performance of genotyping and phenotype-prediction
methods.
Methods: 200 healthy volunteers were exposed to a drug cocktail
containing caffeine, losartan, omeprazole, dextromethorphan and mida-
zolam. A blood sample was obtained after 5 h, urine was collected for
8 h. Subsequent measurement of the above mentioned drugs and their
metabolites allowed calculation of metabolic ratios which were consid-
ered to show the activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6
and CYP3A4/5 respectively. For genotyping, RFLP, qRT-PCR,
pyrosequencing, Affymetrix DMET chips and Illumina exome SNP-
chips were employed.
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Results: Correlation of the Illumina chip data and the phenotype
revealed 10 SNPs that were associated with changes in the metabolic
ratio, most of them surprisingly not within the above-mentioned cyto-
chrome p450 isoenzymes. Concordance of the different genotyping
techniques was only in substantial to almost perfect agreement (j
Fleiss = 0.77–0.88, concordance 94.55% to 97.11%). In our study
cohort, the DMET system could not predict ultra-rapid metabolizers of
CYP2D6 and did not accurately predict poor-metabolizer phenotypes.
Conclusion: Genetic variants in other loci than P450s do not con-
tribute significantly to the variability of metabolic ratios of the probe
drugs. Due to broad variability however, a precise prediction of pheno-
types using genetic data and by applying available algorithms is not
readily possible for all P450 genotypes.
NorPM-P22
METHODOLOGICAL CHALLENGES FOR THE VALUATION
OF DRUG RELATED TREATMENT COSTS FOR RELAPSING
HAEMATOLOGIC CANCER PATIENTS
Laursen H.V.B.1, Vesteghem C.2, Sommer M.3, Nielsen M.M.3,
Dybkær K.2, El-Galaly T.C.3, Johnsen H.E.2, Ehlers L.H.1, Bøgsted M.2
1Danish Center for Healthcare Improvement, Aalborg University,
Aalborg, Denmark; 2Department of Clinical Medicine, Aalborg
University, Aalborg, Denmark; 3Department of Haematology, Aalborg
University Hospital, Aalborg, Denmark
Aims: For up to 3/4 of cancer patients, initial treatments are not effec-
tive, which leads into a trial and error treatment strategy resulting in
unnecessary side effects and a waste of health care resources. How-
ever, little is documented about the costs associated with these sec-
ondary treatments while a large part of the limited hospital resources is
used for them. Our goal is to develop health economics methods to
calculate the cost in order to evaluate the potential savings of imple-
menting precision medicine (PM).
Methods: Since January 1, 2016, relapsing haematologic cancer
patients at Aalborg University Hospital have been offered to participate
in the ProSeq protocol, where RNA- and DNA-sequencing are per-
formed on the cancer cells to identify drug targets. Injectable (IJ) drugs
dosages and prices were obtained from the hospital pharmacy com-
bined with clinical data and dosages for non-IJ drugs from electronic
health records. Data recordings end at death or lost to follow-up. The
drugs were grouped by ATC codes and the price was estimated by a
mg price based on the total number and price of packages and doses
sold to the department. The total drug related treatment cost (DRTC)
over the inclusion period was divided by the total days at risk to get
an estimate of cost per day per patient.
Results: After 25 months, 208 patients have been included. Of these,
111 (myeloid leukemias = 11, lymphoid leukemias = 25, multiple
myeloma = 16, lymphoma = 59) have received drug related treatment.
The included patients have a median follow-up time (95% CI) of
11 months (9.6 months, 13 months) and one-yr survival rate of 76%
(68%, 85%). Assuming 1 year stays in ProSeq the DRTC of relapsing
patients was estimated to be 29 million DKK/year, which is 1/2 of the
DRTC of all haematologic patients.
Conclusion: We have formulated a methodology to estimate DRTC.
This will e.g. be used to 1) identify costly patients, 2) evaluate the
benefit of implementing of PM and 3) aid in health care planning.
NorPM-P23
PHARMACOGENETIC MARKERS OF ADVERSE REACTIONS
OF TYROSINE KINASE INHIBITORS – CASE REPORT
Domjanovic I.K.1, Skvrce N.M.2, Bilusic A.B.2, Ganoci L.3, Bozina N.3,
Sertic D.4
1Department for Assessment of Safety and Efficacy, University
Hospital Centre Zagreb, Zagreb, Croatia; 2Croatian Agency for
Medicinal Products and Medical Devices, University Hospital Centre
Zagreb, Zagreb, Croatia; 3Department of Laboratory Diagnostics,
University Hospital Centre Zagreb, Zagreb, Croatia; 4Department of
Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
Aims: Treatment of chronic myeloid leukemia (CML) is based on
wide range of tyrosine kinase inhibitors (TKIs). The aim of this case-
report is to describe patient with different tolerability to TKIs that
could be explain by pharmacogenetic predisposition. According to lit-
erature, imatinib, nilotinib and dasatinib exhibit distinct interaction pro-
files with ABCB1 and ABCG2 transporters. For bosutinib literature is
discordant whether it is substrate of ABCB1 transporter or not. Addi-
tionally, imatinib is metabolised by CYP2C9, CYP2D6, CYP3A4/5,
while nilotinib, dasatinib and bosutinib by CYP3A4 enzymes.
Methods: A 69-year-old woman was prescribed dasatinib 80 mg/day.
Patient developed following adverse drug reactions (ADRs) malaise,
cough and dyspnoea and subsequently dose was reduced to 40 mg/
day. Adverse drug reactions disappeared on lower doses and dose was
increased to 60 mg/day and 80 mg/day, every second day but adverse
reactions again reoccurred. Dasatinib was stooped and bosutinib was
introduced in dose of 100 mg–400 mg/day without ADRs.
Results: Pharmacogenetic testing (PGX) revealed low expression of
P-gp transporter and intermediate activity of transporter ABCC2 -24C/
T and of enzymes CYP2D6 *1/*4 CYP2C9*1/*3 CYP2C19*1/*2 .
Normal activity was observed for CYP3A4 (tested for*22) and
ABCG2 (tested for 421C>A). Our results suggest that low activity of
P-gp transporter could have contributed to the ADRs of dasatinib but
did not cause ADRs of bosutinib.
Conclusion: This case suggests possible utility of pharmacogenetic
testing to inform prescriber about the TKI with the lowest potential for
ADRs for individual patient. Further research should be done to further
elucidate pharmacogenetic predisposition for ADRs of certain TKIs.
NorPM-P24
OPPORTUNITIES AND CHALLENGES WITH DIRECT-TO-
CONSUMER GENETIC TESTS IN GLOBAL AND
NORWEGIAN PERSPECTIVE
Kiselev Y., Baftiu A., Landmark C.J.
Programme for Pharmacy, OsloMet – Oslo Metropolitan University,
Oslo, Norway
Aims: Direct-to-consumer genetic tests (GTs) have in recent years
been gaining popularity globally and in the Nordic countries. The aim
of this literature analysis was to investigate medical and legal chal-
lenges with GTs.
Methods: A search was performed in PubMed and Google Scholar
from January 2010 to February 2018. Peer-reviewed original articles
and reviews in English were included. EUR-Lex and Lovdata.no data-
bases were used to identify relevant regulations in EU and Norway.
Results: GTs can be purchased at pharmacies or ordered by mail. The
former are usually marketed as diagnostic for specific conditions like
lactose intolerance, indicative towards individual’s metabolic or athletic
properties. None of these tests are currently sold by Norwegian phar-
macies. GTs are also available for ordering online, and usually include
information on predisposition to common diseases, carrier status for
hereditary conditions, response to medications and genogeographic ori-
gin. The largest provider claims to have over 3 million customers. The
major technological disadvantage of most GTs is that only panels of
SNPs are sequenced, which reduces the costs but limits the coverage.
Interpretation of GTs is complicated by the deficient scientific
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evidence and lack of competence among medical professionals. There
is little evidence that taking GTs gives health benefits. Transmission of
personal genetic data to private companies is worrisome Among the
EU countries legislation is diverse from virtually banning GTs to fully
permitting them. In Norway the sale of GTs is not regulated by law,
but testing of children is forbidden.
Conclusion: Most published studies deal with validity of GTs,
bioethics, and legislation. Major challenges with GTs are deficient sci-
entific evidence, low public and professional literacy in genomic health
and vague regulations of GTs. GTs may contribute to early diagnostics
and better health awareness, but progress is necessary in validating
GTs and elaborating regulations.
NorPM-P25
VALPROATE AND PROTEIN BINDING – THE IMPORTANCE
OF MEASURING FREE CONCENTRATIONS
Baftiu A.1,2, Hege K.1,3, Burns M.L.4, Gottas A.4, Johannessen S.I.4,5,
Landmark C.J.1,4,5
1Programme for Pharmacy, Metropolitan University, Oslo, Norway;
2Norwegian Medicines Agency, Oslo, Norway; 3The Norwegian
University of Science and Technology, Trondheim, Norway;
4Department of Pharmacology, Oslo University Hospital, Oslo,
Norway; 5The National Center for Epilepsy, Oslo University Hospital,
Sandvika, Norway
Aims: Routine use of therapeutic drug monitoring (TDM) of
antiepileptic drugs by measurement of total concentrations is well
established in epilepsy. In cases where changes in protein binding
affect highly bound drugs (90% for valproate), measurement of the
unbound concentration will be more accurate for exposure of active
drug in the body. The aim of this study was to describe current prac-
tice where unbound serum concentrations of valproate were measured
and to discuss the clinical impact in patients with epilepsy.
Methods: Retrospective, anonymous TDM-data from patients with
measurements of unbound valproate concentrations were collected
from the National Center for Epilepsy (2012–2017). The samples were
taken drug-fasting in the morning at assumed steady-state. The study
was approved by the Regional Ethics Committee.
Results: Data from 132 measurements in 81 patients using valproate
were included, 40/60% women/men, average age was 39 (1–88) years.
Hypoalbuminemia, reduced renal function, intensive care monitoring,
adverse effects, displacement interaction with stiripentol, young/old age
and pregnancy (5 pregnancies in 3 women) were relevant reasons for
the request. Total serum concentration of valproate was 82–908 µmol/
L (reference range 300–700), average unbound concentration 20% (5–
93, reference 10%), and average dose was 1245 mg/day (72–3,000).
Unbound concentrations of valproate increased up to 5-fold in two
pregnancies and decreased post-partum, reflecting an increased expo-
sure where use of total concentrations would be misleading.
Conclusion: Measurement of total and unbound concentrations of val-
proate showed increased free fraction in most of these vulnerable
patients, and total concentrations may then underestimate drug expo-
sure. Implementation of TDM with total and unbound concentrations
may contribute to improved and tailored treatment for the individual
patient.
NorPM-P26
GENOMIC AIDED PHARMACOTHERAPY (GAP): A PILOT
STUDY IN PATIENTS SUFFERING FROM CHRONIC NON-
CANCER PAIN
Houlind M.B.1, Treldal C.1, Vagn-Hansen L.2, Hansen R.W.3,
Christrup L.L.4
1Department of Drug Design and Pharmacology, University of
Copenhagen, København Ø, Denmark; 2Allevia, Private Hospital
Moelholm, Aarhus, Denmark; 3Kysthosptialet, Skodsborg, Denmark;
4GeneTelligence, Hoersholm, Denmark
Aims: Efficacy and safety of drugs vary significantly between individu-
als. The CYP450 enzyme system is responsible for the metabolism of
most drug substances. During the recent years genetic testing has
become more widely available. In Denmark the genetic test “Person-
alised Medicine Profile” (PMP) was recently made available by
GeneTelligence as a tool to optimise and individualise pharmacother-
apy. PMP is a genotyping test, which translates data on genetic variation
and generates a personalised and evidence-based report on the influence
of genetic variation on drug transport and metabolism by the CYP450
system. The report includes evidence based recommendations for indi-
vidual therapy of 158 commonly prescribed drugs and identify the drugs
that may cause significant side-effects or have reduced efficacy at stan-
dard doses. The patients’ metabolic status is categorised in four classes:
poor -, intermediate -, normal – and ultra rapid metabolisers.
The aim’s of this pilot study was to evaluate the practical issues using
the PMP test and the interpretation of the resulting report in a small
selected population of patients suffering from chronic non-cancer pain
and further to assess the number and types of therapy related chal-
lenges identified by the test.
Methods: Patients were recruited from two private Pain Centres in
Denmark: Allevia and Kysthospitalet during January and February
2018. Eligible patients received a buccal swab kit. After performing
the buccal swab, the kit was sent to GeneTelligence for DNA analysis.
After genomic data translation the personalised evidence-based report
is generated, using the PMP software platform. Based on this PMP
report and the patients’ current medication a pharmacist identified clin-
ically significant drug therapy challenges and created a report contain-
ing recommendations for medication optimisation.
Results: Ten patients were included in this pilot study; the data analy-
ses are still ongoing. The results will be presented at the 1.NORPM
conference.
Conclusion: Conclusions will be presented at the meeting.
NorPM-P27
A CLINICALLY EFFECT OF UGT1A4*3 ON LAMOTRIGINE
CONCENTRATION IS PREDOMINATELY OBSERVED IN
POSTMENOPAUSAL FEMALES – A STUDY OF 534
PATIENTS
Smith R.L., Haslemo T., Chan H., Refsum H., Molden E.
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
Aims: Studies on therapeutic drug monitoring (TDM) of lamotrigine
(LTG) have provided conflicting results regarding the impact of the UDP-
glucuronosyltransferase (UGT) 1A4 genotype on the pharmacokinetics of
LTG. As multiple factors may influence LTG pharmacokinetics, the pre-
sent study aimed to investigate the impact of the UGT1A4*3 variant on
LTG serum concentration accounting for age, sex and valproic acid
(VPA) comedication in a large patient population.
Methods: Matched TDM data on LTG and UGT1A4 genotype of
patients with information about VPA comedication were included ret-
rospectively from a TDM service. Linear mixed model analysis allow-
ing multiple measurements per patients was used to evaluate the
impact of UGT1A4*3, as well as age, sex and VPA comedication, on
dose-adjusted serum concentrations (C/D ratio) of LTG.
Results: Totally, 1735 LTG serum concentration from 534 patients
were included. In the population, UGT1A4*3 carriers had 10–15%
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lower LTG C/D ratio compared to non-carriers (p = 0.01), but the
quantitative impact of UGT1A4*3 depended on age and sex. The dif-
ference was greatest in postmenopausal females (>50 years), where
UGT1A4*3 carriers obtained ~40% lower LTG C/D ratio than
UGT1A4*3 non-carriers (p = 0.001). The UGT1A4*3 variant had only
minor effect on C/D ratio in younger females (≤50 years) and males
(p > 0.1). Regardless of genotype, patients with concomitant use of
VPA had the most pronounced effect by increasing the LTG C/D ratio
about 2.5-fold (p < 0.001).
Conclusion: This study shows that UGT1A4*3 has a modest impact
on LTG exposure, but it could lead to clinically relevant lowering in
serum concentration among postmenopausal females. Thus, genotyping
of UGT1A4 could be valuable for dose individualization when initiat-
ing LTG treatment in postmenopausal females.
NorPM-P29
P-GP INHIBITION INCREASES NEURONAL TOXICITY OF
PACLITAXEL IN SH-SY5Y-DERIVED NEURONS
Stage T.B.1, Khalaf S.2, SvenningsenA.F.2, Kroetz D.3
1Clinical Pharmacology and Pharmacy, Department of Public Health,
University of Southern Denmark, Odense, Denmark; 2Neurobiology,
University of Southern Denmark, Odense, Denmark; 3Department of
Bioengineering and Therapeutic Sciences, University of California San
Francisco, San Francisco, United States
Aims: Paclitaxel is an anticancer agent efficacious in the treatment of
breast, ovarian and lung cancer. ABCB1 polymorphisms have been
associated with increased risk of paclitaxel-induced peripheral neuropa-
thy. The aim of this study was to investigate the link between the drug
efflux transporter P-glycoprotein (P-gp, encoded by ABCB1) and the
neuropathy caused by paclitaxel.
Methods: Neuroblastoma SH-SY5Y cells were differentiated to neu-
rons and treated with 0.1–10 µM paclitaxel for 24 h. Cytotoxicity of
paclitaxel was assessed using the CellTiter-Glo luminescence assay.
The influence of P-gp inhibition during paclitaxel treatment was inves-
tigated by selectively inhibiting P-gp using 4 µM valspodar. Neurons
treated with paclitaxel were immunolabeled with the neuronal marker
tubulin beta III (TUBB3) and the number of neurites/cells were
counted and neurite length measured using ImageJ.
Results: Paclitaxel caused a dose-dependent decrease in both number
and length of neurites in SH-SY5Y-derived neurons, but did not cause
cell death. In SH-SY5Y-derived neurons, 70% had more than two neu-
rites after 0.1 µM paclitaxel exposure, while only 5% of the neurons
had more than two neurites after 10 µM paclitaxel exposure. Neurite
length was also significantly decreased in a dose-dependent manner
(p < 0.01). Inhibiting P-gp led to a marked increased toxicity of pacli-
taxel when assessing both number and length of neurites (p < 0.01).
Conclusion: Paclitaxel caused a clear dose-dependent effect on num-
ber and length of neurites in SH-SY5Y-derived neurons that was exac-
erbated by inhibition of the efflux transporter P-gp. This may
contribute to the understanding of the association of genetic variation
in ABCB1 and paclitaxel-induced peripheral neuropathy.
NorPM-P30
CLINICAL APPLICATIONS OF CYP450 GENOTYPING.
SEVEN YEARS’ EXPERIENCE IN A SWEDISH CLINICAL
SETTING
Scordo M.G.1,2
1Department of Medical Sciences, Clinical Pharmacology, Uppsala
University, Uppsala, Sweden; 2Section for Clinical Pharmakology,
Uppsala University Hospital, Uppsala, Sweden
Aims: Genetics is a known source of interindividual variability in
drug response. Polymorphic enzymes such as CYP2D6, CYP2C19 or
CYP2C9 catalyse the oxidative metabolism of numerous commonly
prescribed drugs, such as antipsychotics, antiepileptics, antidepressants
and cardiovascular drugs. Evaluation of the metabolic capacity of an
individual by genotyping may therefore help the clinicians to select the
right dose and/or the best drug for a patient, thereby minimizing the
risk of side-effects or therapeutic failure.
Methods: In the period 2011–2017 over 700 genotyping analyses were
performed at our Department, with a constant yearly increase in the num-
ber of tests performed. The most requested test was CYP2D6 (47%), fol-
lowed by CYP2C19 (33%) and CYP2C9 (20%). Most patients were
treated with psychoactive drugs (80%), such as antidepressants and classi-
cal antipsychotics, followed by cardiovascular, anticoagulant and antipla-
telet drugs (15%). The principal reason for genotyping was lack of
optimal drug response/therapeutic failure (60%), followed by side-effects
(35%), while a few subjects were genotyped before starting therapy with
drugs such as warfarin, clopidogrel, propafenone or tamoxifen.
Results: Ultrarapid metabolism (caused either by CYP2D6 gene duplica-
tion or homozygosity for CYP2C19*17) was detected in a handful of sub-
jects with therapeutic failure, suggesting that non-compliance plays a major
role in therapeutic failure. Conversely, among subjects who had experi-
enced side-effects, the frequency of detrimental alleles was higher than the
background incidence. Furthermore, in some cases extensive metabolisers
with side effects were phenotypically poor metabolisers, due to co-medica-
tion with potent CYP2D6 inhibitors such as paroxetine and bupropion.
Conclusion: Based on our experience, we conclude that genotyping is
a valuable complement to plasma concentration determination when
poor or ultrarapid drug metabolism is suspected.
NorPM-O1
EFFECT OF RARE SINGLE-NUCLEOTIDE VARIANTS ON
THE BREAST CANCER RESISTANCE PROTEIN
Sj€ostedt N.1, Timmermans R.1, Lepp€anen R.1, van den Heuvel
J.J.M.W.2, Koenderink J.2, Kidron H.1
1Faculty of Pharmacy, University of Helsinki, Helsinki, Finland;
2Radboud University Medical Centre, Nijmegen, Netherlands
Aims: To study the effect of single-nucleotide variations in transmem-
brane regions and the first intracellular loop of the breast cancer resis-
tance protein (BCRP, ABCG2).
Methods: Nine naturally occurring variants in the transmembrane
region of BCRP (G406R, F431L, S441N, P480L, F489L, M515R,
L525R, A528T and T542A) and five in the first intracellular loop
(K453R, I456V, H457R, G462R and G462V) were selected. In addi-
tion, two common variants (V12M and Q141K) in the nucleotide bind-
ing domain were included as controls. The variant proteins were
expressed using a baculovirus expression system in mammalian cells
(HEK293). Crude membrane fractions of the cells were extracted to
prepare membrane vesicles. Western blotting and immunofluorescence
microscopy were used to study the expression and localization of the
variants. The activity of the variants was tested using the vesicular
transport assay with BCRP substrates Lucifer yellow and estrone sul-
fate. The data was used to predict in vivo effects of the BCRP variants
on rosuvastatin pharmacokinetics in two PBPK models using Simcyp
and MATLAB SimBiology.
Results: The transport activity of all variants in the transmembrane
region was significantly impaired compared to wt BCRP, but two of
the variants (K453R, I456V) in the intracellular loop retained compara-
ble activity to wt BCRP. Decreased expression levels could explain
the low activity for some, but not all, of the variants. Immunofluores-
cence studies in cells indicated impaired localization for some of the
variants, in line with the activity and Western blot results. Based on
the simulations, variants with impaired activity may increase the Cmax
of rosuvastatin by two-fold and the AUC over three-fold compared to
the wt BCRP.
Conclusion: Single nucleotide variations in the transmembrane region
or the first intracellular loop may have destructive effects on BCRP
activity, which may lead to unexpected pharmacokinetic events in
patients carrying these variants.
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NorPM-O2
DOXORUBICIN UPTAKE IN CARDIOMYOCYTES IS
DEPENDENT ON ORGANIC CATION TRANSPORTER 3
Huang K.1, Magdy T.2, Bonilla I.3, Hu S.1, Gibson A.1, Carnes C.3,
Sparreboom A.1, Burridge P.2
1Pharmaceutics, The Ohio State University, Columbus, OH, United
States; 2Pharmacology, Northwestern University, Chicago, OH, United
States; 3Pharmacology, The Ohio State University, Columbus, IL,
United States
Aims: The anthracycline doxorubicin is among the most effective and
commonly used anticancer agents, but its use is associated with a
potentially life-threatening cardiotoxicity. We hypothesized that dox-
orubicin-induced cardiotoxicity (DIC) is initiated by transporter-
mediated mechanism in which cells of the myocardium are selectively
damaged, and that identification of the involved solute carriers can
provide insights into the development of preventative strategies.
Methods: Transporter gene expression studies were conducted on
human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) from patients that did or did not experience DIC. Determination
of transport kinetics and mechanism of transport inhibition were per-
formed in stably transfected HEK293 using TEA and metformin as
prototypical substrates. Furthermore, doxorubicin disposition in ex vivo
isolated cardiomyocytes and in vivo hearts were determined in wild-
type and age-matched transporter-knockout mice.
Results: Multiple solute carrier genes were overexpressed by ≥2-fold
in hiPSC-CMs from patients experiencing DIC, including OCTN1,
OCT1, and OCT3. Among these transporters, deficiency of OCT3 in
mouse cardiomyocytes was associated with the most significant
decrease in doxorubicin uptake ex vivo (p < 0.0001). Accumulation of
doxorubicin in cardiomyocytes of wild-type mice could be inhibited
by known OCT3 inhibitors, including the tyrosine kinase inhibitors
dasatinib and nilotinib, through a non-competitive mechanism. Consis-
tently, heart levels were reduced in OCT3-knockout mice after doxoru-
bicin administration in vivo.
Conclusion: We identified a previously unrecognized pathway of DIC
that is initiated by an organic cation transporter system and highly sensi-
tive to pharmacological inhibition. These findings shed further light on the
etiology of DIC, and provide a rationale for the future development of
new targeted interventions to mitigate this debilitating side effect.
NorPM-O3
MICRORNA-155 CONTROLS VINCRISTINE SENSITIVITY
AND PREDICTS SUPERIOR CLINICAL OUTCOME IN
DIFFUSE LARGE B-CELL LYMPHOMA
Due H.1, Sch€onherz A.A.1, Ryø L.B.2, Roug A.S.1, Johnsen H.E.1,
Bøgsted M.1, Mikkelsen J.G.2, Dybkær K.1
1Department of Hematology, Aalborg University Hospital, Aalborg,
Denmark; 2Department of Biomedicine, Aarhus University, Aarhus,
Denmark
Aims: A major clinical challenge of diffuse large B-cell lymphoma
(DLBCL) is that 30–40% of patients have refractory disease or relapse
after initial response to therapy, due to drug-specific molecular resis-
tance. The purpose of this study was to investigate miRNA involve-
ment in vincristine resistance in DLBCL.
Methods: By analyses of miRNA microarrays from DLBCL cell lines
with different vincristine sensitivity, we identified lower miR-155 expres-
sion in resistant cells. This association was further examined by functional
in vitro analysis, studying the direct impact of miR-155 in vincristine
response, and by target gene analysis. Secondly, prognostic impact of
miR-155 expression was evaluated in two independent DLBCL cohorts.
Results: Exogenous upregulation of miR-155 sensitized GCB-DLBCL
cells to vincristine, and consistently, downregulation and knock-out of
miR-155 induced vincristine resistance, documenting that miR-155
functionally controls vincristine sensitivity. Target gene analysis identi-
fied Wee1, a cell-cycle checkpoint gene, as a target of miR-155 in
DLBCL. Chemical inhibition of Wee1 sensitized GCB-DLBCL cells
to vincristine, suggesting that miR-155 controls vincristine response
through Wee1. Clinical outcome analysis of DLBCL patients revealed
that high miR-155 expression level was significantly associated with
superior survival for R-CHOP treated patients of the GCB subclass,
independent of the well-established international prognostic index
(IPI), an observation challenging the commonly accepted perception of
miR-155 as an oncomiR.
Conclusion: We experimentally confirmed a direct link between high
miR-155 expression and vincristine sensitivity in DLBCL and docu-
mented an improved clinical outcome of GCB classified patients with
high miR-155 expression level. This suggests that the role of miR-155
in vincristine response is important enough to affect overall survival.
NorPM-O4
THE PROTEIN KINASE INHIBITORS MIDOSTAURIN AND
NINTEDANIB ARE TIME-DEPENDENT INHIBITORS OF
CYP3A4
Filppula A., Mustonen T., Backman J.
Department of Clinical Pharmacology, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland
Aims: Protein kinase inhibitors display a tendency to affect cyto-
chrome P450 (CYP) 3A4 by time-dependent inhibition. As CYP2C8
and CYP3A4 share overlapping substrate specificity, we tested six
novel kinase inhibitors for time-dependent inhibition of these enzymes.
Methods: The inhibitory effects of dovitinib, masitinib, midostaurin,
nintedanib, trametinib and vatalanib on amodiaquine N-deethylation
(CYP2C8) and midazolam 1’-hydroxylation (CYP3A4) were evaluated
in human liver microsomes. Static predictions were used to estimate
the clinical significance of the observed inhibition.
Results: Dovitinib, midostaurin and nintedanib exhibited time-dependent
inhibition of CYP3A4 (IC50 shift >1.5), whereas masitinib, trametinib and
vatalanib did not affect CYP2C8 or CYP3A4 by time-dependent inhibi-
tion (IC50 shift <1.5). Further experiments identified midostaurin and nin-
tedanib as mechanism-based inhibitors of CYP3A4, with maximal
inactivation rate (kinact) and inhibitor concentration supporting half of kinact
(KI) values of 0.052 1/min and 2.72 µM, and 0.025 1/min and 17.3 µM,
respectively. Predictions indicated that standard doses of nintedanib are
unlikely to cause drug interactions with CYP3A4-dependent substrates,
whereas midostaurin could increase the plasma exposure to such sub-
strates several-fold. Furthermore, based on reversible inhibition, masitinib
and vatalanib were predicted to increase the plasma exposure to sensitive
CYP2C8 and CYP3A4 substrates by ≥2-fold.
Conclusion: Our data identifies two additional kinase inhibitors as
time-dependent inhibitors of CYP3A4, and detects a risk for drug
interactions between several of the tested inhibitors and CYP2C8 and
CYP3A4 substrates.
NorPM-O5
GENOME-WIDE ASSOCIATION STUDY OF PANDEMRIX-
INDUCED NARCOLEPSY IN SWEDEN – A POSSIBLE ROLE
FOR GLIAL DERIVED NEUROTROPHIC FACTOR (GDNF)
Wadelius M.1, Eriksson N.2, Smedje H.3, Yue Q.-Y.4, Magnusson
P.K.E.5, Hallberg P.1
1Medical Sciences and Science for Life Laboratory, Uppsala
University, Uppsala, Sweden; 2Uppsala Clinical Research Center,
Uppsala University, Uppsala, Sweden; 3Division of Child and
Adolescent Psychiatry, Karolinska Institutet, Stockholm, Sweden;
4Medical Products Agency, Uppsala, Sweden; 5Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,
Sweden
Aims: Narcolepsy is an autoimmune disease characterized by an
inability to control sleep and wakefulness. The number of young
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diagnosed with narcolepsy rose sharply following immunization with
the A(H1N1)pdm09 influenza virus strain vaccine Pandemrix in Swe-
den 2009–2010. The most frequent form, narcolepsy type I, is known
to be caused by a loss of hypocretin neurons, and is strongly associ-
ated with HLA-DQB1*0602. However, only 0.02 % of HLA-
DQB1*0602 carriers developed narcolepsy following vaccination. We
sought to determine whether other genetic factors contribute to the risk
of narcolepsy associated with Pandemrix.
Methods: 43 adjudicated cases of Pandemrix-associated narcolepsy
from the Swedish adverse drug reaction biobank Swedegene were
compared with 4891 Swedish population controls from TwinGene.
Genotyping was performed on Illumina arrays. The merged dataset
contained 600 K single nucleotide polymorphisms (SNPs), and after
phasing and imputation 8.6 million SNPs. We corrected for principal
components 1–4. The genome-wide significance p-value threshold was
set to p < 5 9 108.
Results: Narcolepsy was significantly associated with HLA-
DQB1*0602, odds ratio (OR) 6.4 [95% confidence interval (CI) 4.2,
9.8], p = 1.4 9 1017. After correction for HLA-DQB1*0602, the
strongest association was with the glial cell line-derived neurotrophic
factor antisense gene (GDNF-AS1), OR=8.6 [95% CI 4.2, 17.6],
p = 2.6 9 109.
Conclusion: We found an association with an antisense RNA that is
transcribed from the opposite stand of the glial cell line-derived neu-
rotrophic factor gene (GDNF). The antisense transcript has been shown
to regulate the expression of GDNF, which encodes an essential neu-
rotrophic factor that supports neuronal survival. Dysregulation of
GDNF has been seen in brain cells from patients with Alzheimer’s and
Parkinson’s disease. This finding may increase the understanding of
mechanisms behind vulnerability to narcolepsy.
NorPM-O6
CLINICAL IMPLEMENTATION OF PERSONALIZED
MEDICINE BY NOVEL APPROACHES IN THERAPEUTIC
DRUG MONITORING (TDM)
Eliasson E., Pohanka A., Dahl M.-L., Lindh J., Beck O.
Laboratory Medicine, Karolinska Institutet, Clinical Pharmacology
Karolinska University Hospital , Stockholm, Sweden
Aims: One of the most important aspects of personalized medicine is
the identification of optimal dose. While inter-patient variability in
pharmacokinetics is substantial and multifactorial, high-precision pre-
dictive markers of the optimal individual dose are often lacking. Bio-
analysis of drug/drug metabolite concentrations will play an important
role for individual dosing and the aim of this presentation is to sum-
marize recent developments in TDM methodology.
Methods: There has been a dramatic development in bioanalysis
based on mass spectrometry (MS). Multi-component detection methods
with high accuracy and precision are now clinical routine. High-resolu-
tion (HR-)MS will allow for detection and quantification of essentially
all low-molecular weight molecules in a single sample. Obvious appli-
cations include intoxications, monitoring of polytherapy and patient
compliance. New sampling methodology include dried blood spots and
exhaled breath particles derived from lung epithelial lining fluid. Popu-
lation pharmacokinetics-based models will improve area-under-the-con-
centration-time-curve (AUC) estimations and increase flexibility in
sampling time.
Results: There is an increasing demand of the Karolinska TDM labo-
ratory with last year approaching 75,000 analyses including around
1,300 genotyping requests on TPMT or CYP. At present, we quantify
the systemic concentration of 120–150 different agents. The major
therapeutic areas are immune-modulating drugs, antiepileptics, antimi-
crobials and psychoactive drugs. Much work is also spent on IT-solu-
tions for correct in-data and reports. TDM-sampling indications are
specified together with clinicians, and results interpretations rely on
updated reviews of the scientific literature.
Conclusion: TDM is under strong development and receives an
increased clinical interest. TDM provides the tool for more precise dose
adjustments in the individual case, and may work well in tandem with
pharmacogenetic approaches that aim to individualize starting dose.
NorPM-O7
SELECTING PHARMACOGENETIC TEST FOR
CLOPIDOGREL PATIENTS
Forsström J.1, Tulkki M.2
1Abomic Oy, University of Turku, Turku, Finland; 2Department of
Biochemistry, University of Turku, Turku, Finland
Aims: Clopidogrel is a pro-drug which is metabolized by CYP2C19
to an active substance. About 30% of European population are poor or
intermediate CYP2C19 metabolizers. For them the effect of clopido-
grel may be absent or poor and testing of CYP2C19 is therefore rec-
ommended. Patients using clopidogrel often use other drugs as well.
Based on epidemiological data we evaluated, how often the patient
would benefit from a larger pharmacogenetic profile compared to
CYP2C19 definition alone.
Methods: From Finnish prescription statistics we collected all pre-
scriptions from over 30 cities in Finland. It covered 20% of the Fin-
nish population. All patients who had received clopidogrel prescription
in 2015–2017 were selected. From these patients we calculated, how
many patients had received in the same period a drug where defining
CYP2D6 or SLCO1B1 is recommended. According to Finnish data-
base the substances where CYP2D6 is recommended are: amitriptyline,
codeine, metoprolol, nortriptyline, paroxetine, risperidone and tamox-
ifen. SLCO1B1 is recommended for simvastatin patients.
Results: In the material we found 17.373 patient who had a clopido-
grel prescription. 6,547 patients (37.7%) had only clopidogrel prescrip-
tions. 5,105 patients (29.4 %) had at least one prescription of drugs
where CYP2D6 is recommended. The four most commonly used
CYP2D6 drugs in the clopidogrel population were: metoprolol (2,089),
codeine (1,876), amitriptyline (1,037) and risperidone (674). In the pop-
ulation we had 5,503 patients (31.7%) who had received simvastatin.
Conclusion: Clopidogrel patients often have other drugs where pharma-
cogenetics testing would be beneficial. Based on our data it is evident, that
the population would benefit from larger set of pharmacogenetic tests. At
least CYP2D6 and SLCO1B1 are relevant in this patient population. When
the test is performed from the same sample, the additional testing cost is
minimal compared to the benefit for the patient and health care payers.
NorPM-O8
GLP-1 RECEPTOR VARIANTS MARKEDLY
DIFFERENTIATE GLYCAEMIC RESPONSE TO GLP-1
RECEPTOR AGONISTS: A DIRECT STUDY
Dawed A.Y.1, Mari A.2, McDonald T.J.3, Hong M.-G.4, Sharma S.5,
Robertson N.R.6, Mahajan A.6, Walker M.7, Gough S.8, Zhou K.9,
Forgie I.9, R€utten H.10, Jones A.G.3, Pearson E.R.9
1Molecular and Clinical Medicine, University of Dundee, Dundee,
United Kingdom; 2CNR Institute of Neuroscience, Padua, Italy;
3NIHR Exeter Clinical Research Facility, Royal Devon and Exeter
Hospital, Exeter; 4Affinity Proteomics, Science for Life Laboratory,
School of Biotechnology, KTH-Royal Institute of Technology, Solna,
United Kingdom; 5Research Unit of Molecular Epidemiology, Institute
of Epidemiology II , Helmholtz Zentrum Muenchen, Germany;
6Wellcome Trust Centre for Human Genetics, University of Oxford,
Oxford; 7Institute of Cellular Medicine, Newcastle University,
Newcastle upon Tyne; 8Oxford Centre for Diabetes Endocrinology and
Metabolism, NIHR Oxford Biomedical Research Centre, Oxford;
9Molecular and Clinical Medicine, University of Dundee, Dundee,
United Kingdom; 10Sanofi-Aventis Deutschland GmbH, TMED,
Frankfurt, Germany
Aims: Glycaemic response to GLP-1 Receptor Agonist (GLP-1RA)
treatment varies markedly among patients with Type 2 Diabetes (T2D)
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yet the mechanism for this variation is uncertain and only short-term
glycaemic response can predict who will have a merked mid-long-term
response and who will respond less. Common missense variants in the
GLP-1R have previously been reported to alter GLP-1 mediated insu-
lin secretion in non-diabetic individuals. We aimed to investigate how
GLP-1R variants alter glycaemic response to the GLP-1RA.
Methods: We performed a meta-analysis across the DIRECT, PRIBA
and GoDARTS cohorts. A total of 1,156 T2D subjects were followed-
up for 6 months after initiation of GLP-1RA treatment. The association
of GLP-1R variants, rs6923761 (Gly168Ser) and rs10305420 (Pro7-
Leu), with reduction in glycated haemoglobin (HbA1c) after treatment
were assessed using multiple linear regression in an additive model.
Results: Gly168Ser and Pro7Leu variants were independently associ-
ated with reduced efficacy of GLP-1RA to lower HbA1c (Gly168Ser
b (HbA1c change per allele) = 0.18%, p = 0.001, Pro7Leu
b = 0.14%, p = 0.01). We then derived a genetic risk score, sum-
ming up these two variants. The 22% of the population who carry no
variant allele in either of the variants had a mean HbA1c reduction
of (1.39%[1.21–1.58] (15.22 mmol/mol [13.17–17.27])). In contrast
the 17% percent of the population who carry 3 or more risk alleles
had a much lower glycaemic response (0.86% [0.66–1.13]
(9.4 mmol/mol [7.00–11.92])), a difference of 0.53% [5.8 mmol/mol]
(p < 0.001). There was no significant impact of these SNPs on
weight change in response to GLP-1RA suggesting the variants
impact on the glycaemic lowering mechanisms of GLP-1RA rather
than weight lowering mechanisms.
Conclusion: Missense variants in the GLP-1R have a large clinical
impact on glycaemic response to GLP-1RA. The frequencies of these
variants are not rare, making this the largest, most common pharmaco-
genetic effect described to date in T2D.
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